Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

If you will be receiving chemotherapy over a long period of time, or if you are a candidate for a blood or marrow transplantation, your healthcare provider may recommend a central line, or central ...

Inari shareholders are getting a fair price ... with a primary focus on stroke and aneurysm treatment including coils, catheters, microcatheters, stents, and mechanical thrombectomy devices.

In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 14.20% Downside As of ...

The deal for Bolt Medical is the second big medtech acquisition unveiled this week, following Stryker’s $4.9 billion purchase of Inari Medical on Monday ... acoustic pressure waves inside of a balloon ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

Beta Bionics, a significant player in the automated insulin delivery space, announced that it aims to become a publicly traded company. Our sister site, Drug Delivery Business News, reports today ...

Inari, based in Irvine, California, makes a variety of devices including catheter-based mechanical thrombectomy systems to treat vascular disease. Stryker, which has a larger orthopedics business, ...